344 related articles for article (PubMed ID: 27288116)
1. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Honda Y; Kamisato C; Morishima Y
Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
[TBL] [Abstract][Full Text] [Related]
2. Prevention of Stent Thrombosis in Rats by a Direct Oral Factor Xa Inhibitor Edoxaban.
Morishima Y; Honda Y; Kamisato C
Pharmacology; 2019; 103(1-2):17-22. PubMed ID: 30343300
[TBL] [Abstract][Full Text] [Related]
3. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Morishima Y; Kamisato C; Honda Y
Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Moll F; Baumgartner I; Jaff M; Nwachuku C; Tangelder M; Ansel G; Adams G; Zeller T; Rundback J; Grosso M; Lin M; Mercur MF; Minar E;
J Endovasc Ther; 2018 Apr; 25(2):158-168. PubMed ID: 29552984
[TBL] [Abstract][Full Text] [Related]
5. Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
Honda Y; Morishima Y
Thromb Res; 2015 May; 135(5):958-62. PubMed ID: 25791908
[TBL] [Abstract][Full Text] [Related]
6. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
10. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban: a focused review of its clinical pharmacology.
Lip GY; Agnelli G
Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Fukuda T; Tsuji N; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1062-8. PubMed ID: 21946952
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Wåhlander K; Eriksson-Lepkowska M; Nyström P; Eriksson UG; Sarich TC; Badimon JJ; Kalies I; Elg M; Bylock A
Thromb Haemost; 2006 Mar; 95(3):447-53. PubMed ID: 16525572
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
15. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Wong PC; Crain EJ; Watson CA; Wexler RR; Lam PY; Quan ML; Knabb RM
J Thromb Thrombolysis; 2007 Aug; 24(1):43-51. PubMed ID: 17323133
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Shirasaki Y; Morishima Y; Shibano T
Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
[TBL] [Abstract][Full Text] [Related]
17. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
[TBL] [Abstract][Full Text] [Related]
18. Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Franchi F; Rollini F; Garcia E; Rivas Rios J; Rivas A; Agarwal M; Kureti M; Nagaraju D; Wali M; Briceno M; Moon JY; Kairouz V; Yaranov D; Been L; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Thromb Haemost; 2020 Jan; 120(1):83-93. PubMed ID: 31470444
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats.
Morishima Y; Shibutani T; Noguchi K; Ito Y; Honda Y
J Thromb Thrombolysis; 2021 Jul; 52(1):9-17. PubMed ID: 33534029
[TBL] [Abstract][Full Text] [Related]
20. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits.
Wong PC; Watson CA; Crain EJ
J Thromb Haemost; 2008 Oct; 6(10):1736-41. PubMed ID: 18647224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
